TXL Experiment Summary

Study 1: Immunomodulation Effect

Study Period: March 1, 2000 –Feb. 28, 2001
Subject: Immunomodulation of PBMC (peripheral blood mononuclear cell) and T cell
Conclusion: The immunomodulation effects for auto-immune disease or infection were much better than AHCC (Active Hexose Correlated compound) and PSK (polysaccharide-Kureha)

Study 2: Cytotoxic Effect on Cancer Cell

Study Period: Nov. 1, 2000 – OCT. 31, 2001
Subject: Cytotoxic effect on cancer cell (K562, U937, MT-2, CT26/RT1)
Conclusion: Tien Hsien liquid could activate immunocytes effectively in orer to destroy cancer cell without damaging normal cell.

Study 3: Cancer Cell Proliferation Inhibition as Well as Apoptosis Induction

Study Period: Nov. 1, 2001 – Oct. 31, 2002
Subject: inhibit 15 types of human cancer cell proliferation and induce apoptosis
Conclusion: Tien Hsien Liquid can induce apoptosis of 15 types of human cancer cells while maintaining the growth of normal cells.

Study 4: Inhibition of Cancer Cell Growth

Study Period: Nov. 1, 2002 – Oct. 31, 2003
Subject: inihibit cancer cell growth and induce poptosis
Conclusion: Tien Hsien Liquid can inhibit cancer cell growth and activate lymphocyte T cell effectively.

Study 5: Inhibit Cancer Cell Recurrence and Metastasis

Study Period: Nov. 1, 2003 – June 30, 2004
Subject: increase immunocompetenceand inhibit cancer cell activation as well as metastasis
Conclusion: Tien Hsien Liquid can increase Lymphocyte T cell activation of and inhibit the cancer cell invasion and metastasis

Study 6: Inhibition of Cancer Cell Induced Timorous Angiogenesis

Study period: April 1, 2004 – March 31, 2005
Subject: inhibit the movement of the pathological vascular endothelial cells 
Conclusion: Tien Hsien Liquid can inhibit cancer cell growth effectively and induce timorous anti-angiogenesis.

Study 7: Inhibit Tumor Metasis in vitro / in vivo

Study Period: Jan. 1, 2007 – Dec. 31, 2007
Subject: inhibit human colorectal carcinoma cell CT-26 metastasis on Severe Combined Immune-Deficiency (SCID) mice
Conclusion: Tien Hsien Liquid can inhibit tumor metastasis in vitro / in vivo

Study 8: Inhibit the Immunocompetence of Cancer Cell

Study Period: Sept. 1, 2010 – Aug. 31, 2012
Subject: Combination of Tien Hsien Liquid and Chemotherapy can increase immunocompetence, eliminate cancel cell and prevent cancer recurrence
Conclusion: Proceeding.

The study (1-8) was carried out and completed by the Ching-Hsing Medical Foundation.
Member:
Advisor Professorr: Zhao-Xiong, Yang
Honorary Professor of National Taiwan University, College of Medicine
President of Ching-Hsing Medical Foundation
Former Dean of National Taiwan University, College of Medicine
Co-organizers: Won-Bo, Wang
Professor of Graduate Institute of Microbiology, National Taiwan University, College of Medicine 
Postdoctoral Fellow of Tumor at Dana Farber Cancer Center, Harvard Medical School, USA PhD of Microbiology of Purdue University, USA
Chun-Pin, Chiang
Attending Physician of Oral Cavity/Dental Dept. , National Taiwan University Hospital 
Professor of Dental Dept. , National Taiwan University
Medicine Phd, Harvard Medical School, USA
Andy Sun
PhD of Immunnology, National Taiwan University, College of Medicine
Attending Physician of Oral Cavity, National Taiwan University Hospital
Visiting Professor of Shanghai University of Traditional Chinese Medicine
Jean-San Chia
Professor of Graduate Institute of Microbiology, National Taiwan University, College of Medicine 
Dentist of National Taiwan University Hospital
PhD of Immunology, National Taiwan University, College of Medicine

Study 9: Multiple Molecular Target Effects on Inhibiting Cancer Stem Cells (Sec 1)

Study Period: Jan 1, 2006 – Dec. 31, 2—6
Subject: induce apoptosis and Inhibit cancer cell by activated protein on an oncogenic signal transduction
Conclusion: Tien Hsien Liquid can decompose PML-PAR α and integrate it with the protein to inhibit acute promyelocytic leukemia NB4 through the tumor oncogenic signal transduction and inhibit NB4 cell growth. It can also block breast cancer cell and brain glioma cancer cell signal transduction (ERK,Akt/mTOR, STAT3, EGFR)

Study 10: Multiple Molecular Target Effects on Inhibiting Cancer Stem Cells (Sec 2)

Study Period: March 1, 2006 – Dec. 31, 2006
Subject: inhibit breast cancer cell growth as well as induce Apoptosis
Conclusion: Tien Hsien Liquid can inhibit the DNA of HMT 1 and the phosphorylation function of protein kinase B; stimulate the breast cancer cell suppress genes overstimulated by methyl and reduce the stimulation occurred by methyl effectively so that chemotherapy can be stopped and MCF-7 can be inhibited.

Study 11: Multiple Molecular Targe Effects on Inhibiting Cancer Stem Cells (Sec 3)

Study Period: Aug. 1, 2006 – July 31, 2007
Subject: increase radiation sensitivity
Conclusion: Tien Hsien Liquid can inhibit the Rad51 of protein repairing enzymes and increase radiation sensitivity.

Study 12: Multiple Molecular Target Effects on Inhibiting Cancer Stem Cells (Sec 4)

Study Period: March 1, 2007 – Feb. 29, 2008
Subject: Eliminate cancer stem-like cell (side population cell)
Conclusion: Tien Hsien Liquid can eliminate cancer stem cell can has poten tiel to ptrevent cancer cell recurrence.

Study 13: Mulitple Molecular Target Effects on Inhibiting Cancer Stem Cells (Sec 5)

Study Period: April 1, 2007 – April 30, 2008
Subject: induce cancer stem-like cell disintegration and stimulate appetite
Conclusion: Tien Hsien Liquid can activate PPAR-ϒ (peroxisome proliferator activated receptors- ϒ) and estimate the potentiality of benign disintegration of cancer cell. It can also activate the AMP-dependent Kinase Thereby stimulating the appetite.

The study (9-13) was carried out and completed in cancer study by the National Health Research Institute led by Lai Ji-ming, the associate researcher.
Member:
Project Leader: Gi-ming Lai
Director of Hematologica Tumor Dept .,
Shuang-Ho-Hospital
CEO of Formosa Cancer Foundation Associate 
Researcher of the National Health Research Institutes
Project Executors: Chih- Jung Yao 
Formosa Cancer Foundation 
Chi-Tai yeh, National Health Research Institutes
Jiann-Long Yan, National Health Research Institutes

Study 14: T Lymphocyte Activation (Pro-Clinical Study)

Study period: Aug. 1, 2003 – July 31, 2004
Subject: Evaluation of T lymphocyte activation 
Conclusion:
The average curative effect of patient achieved 45.7%
The curative effect of breast cancer patients achieved 83.3%
Tien Hsien Liquid can increase cancer patients’ T lymphocyte activation.

Project Leader: Chi-Yuan yeh 
Master of Medical Science, Taipei Medical University
Directory of Tumor Center, Tung’s Taichung MetroHarbor Hospital

Study 15: Effect on Breast Cancer Cell BR755

Study Period: March 12, 2004 – Sept. 9, 2004
Subject: inhibit breast cancer cell BR755
Conclusion: Tien Hsien Liquid can inhibit breast cancer cell BR755 effectively in vivo.

Project Leader: Yamazaki Noriyuki
Director of New Drug Development Research Center 
Inc. at Hokkaido, Japan 
Vice Director of Clinical Dept. , New Drug Development 
Research Center Inc. at Hokkaido, Japan

Study 16: Effect on Cancer Reversion

Study Period: Jan. 1, 2007 – April 30, 2008
Subject: The application of molecular medicine angiography technology helps to understand the clinical efficacy evaluation and cancer reversion after taking Tien Hsien Liquid.
Conclusion: After the test result of the MTT assay, the H441GL, one of the lung cancer cell lines achieved 50% after taking 0.15% of Tien Hsien Liquid. The thickness of Tien Hsien Liquid impacts the cycle of the lung cancer cell and induces apoptosis.

Project Leader: Deng Wen-Bing
Dean of school of Medical Lab. Science & 
Biotechnology, Taipei Medical University
PhD in biology of Cancer, Harvard University, USA

Study 17: Inhibit the Cancer Cell of The Alimentary Canal

Study Period: Feb. 1, 2008 – Jan. 31, 2009
Subject: inhibit HT29 cancer cell in the alimentary canal and its MMP-1, MDR-1, p21 in vitro/ in vivo
Conclusion: Tien Hsien Liquid can inhibit tumor growth and tumorous angiogenesis it has the potential to prevent colorectal cancer recurrence by decreasing drug resistance.

Study 18: Colorectal cancer on the Synergy in vitro/ in vivo

Study period: Jan 12, 2010 – Jan. 11, 2011
Subject: To determent if the three types of permeation of Tien Hsien can prevent colorectal cancer drug resistance in vitro/ in vivo, such as proliferation, invasion, metastasis and reversion of cancer cell.
Conclusion: The synergy of Tien Hsien Liquid is well developed in its three permeations; the effect of the original liquid is stronger than the three liquid versions. Tien Hsien Liquid can inhibit proliferation, invasion and metastasis of tumors and reduce the tolerance in an experimental mouse. The average size of colorectal cancer is largely reduced but the average weight of mice still remains the same.

The study (17-18) was carried out and completed by the School of Chinese Medicine, the University of Hong Kong.
Member:
Project leader: Yao Tong 
Dean of School of Chinese Medicine, the University of Hong Kong
Medicine PhD of Shanghai University of Traditional Chinese Medicine
Project Executors: Stephen C.W. Sze
Lab Director of School of Chinese Medicine, the University of Hong Kong
Phd in Anatomy

Study 19: Toxicity experiment

Study period: Nov. 29, 2007 – Feb. 1, 2008
Subject: 
Erythrocyte micronucleus test in vivo
Ames test to reverse the mutation of gram negative aerobic bacteria
Chromosomal abnormality analysis test on mammal cell in vitro. Conclusion: No toxicity of chromosomal genes to erythrocytes in vivo. No variability in Ames test to reverse mutation of gram negative aerobic bacteria; cell gene mutation revealed negative reaction. No variability in mammal cell test in vitro. This toxicity experiment guaranteed the safety of Tien Hsien Liuid

Project Leader: Jiunn-Wang Liao
Associate Professor of Animal Diseases Diagnostic Center, National Chung Hsing University, College of Veterinary Medicine

Study 20: Analysis on Inhibition of Hepatitis B Virus’s Activity by THL

Study period: Dec. 20, 2007 – Feb. 29, 2008
Subject: Inhibit hepatitis B virus
Conclusion: Tien Hsien Liquid can inhibit the activation secretions of HBeAg. It inhibits the activation of hepatitis B’s virus in vitro.

Project leader: Shau-Feng Chang
Director of Pharmacological Study, Institute of Biotechnology and Pharmaceutical, Industrial Technology Research Institute, Taiwan

♥ Follow our facebook page for more information: https://www.facebook.com/tianxian/